# TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

> **NCT05550025** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 26 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** camrelizumab& apatinib

## Key facts

- **NCT ID:** NCT05550025
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-17
- **Primary completion:** 2023-11-11
- **Final completion:** 2024-02-11
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2022-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05550025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05550025, "TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05550025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*